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Abstract (147 words) 
Influenza viruses are major human pathogens responsible for respiratory diseases affecting millions 
of people worldwide and characterized by high morbidity and significant mortality. Influenza 
infections can be controlled by vaccination and antiviral drugs. However, vaccines need annual 
updating and give limited protection. Only two classes of drugs are currently approved for the 
treatment of influenza: M2 ion channel blockers and neuraminidase inhibitors. However, they are 
often associated with limited efficacy and adverse side effects. In addition, the currently available 
drugs suffer from rapid and extensive emergence of drug resistance. All this highlights the urgent 
need for developing new antiviral strategies with novel mechanisms of action and with reduced 
drug resistance potential. Several new classes of antiviral agents targeting viral replication 
mechanisms or cellular proteins/processes are under development. This review gives an overview of 
novel strategies targeting the virus and/or the host cell for counteracting influenza virus infection. 
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Introduction 
Influenza viruses (IV) represent one of the major threats to public health, as they are responsible for 
both epidemics and pandemics characterized by high morbidity and mortality. During the past 
century, the pandemics of Spanish flu (1918), Asian flu (1957), Hong Kong flu (1968), bird flu 
(2005), and recently, swine flu (2009) caused millions of deaths worldwide [1]. In addition, the 
seasonal influenza epidemic results in hundreds of thousands of deaths per year 
(http://www.who.int/). IV belong to the Orthomyxoviridae family and include A, B, and C types, 
which differ in host range and pathogenicity. In particular, influenza A viruses (IAV) infect a wide 
range of avian and mammalian hosts, while influenza B viruses (IBV) infect almost exclusively 
humans. IAV are further classified into subtypes based on the antigenic properties of two viral 
surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA): 17 HA (H1–H17) and 10 NA 
(N1–N10) antigenic subtypes have been identified so far [2]. Within a subtype, different strains can 
arise as a result of point mutations; indeed, IAV evolve constantly and new mutant strains replace 
the old ones in a process known as “genetic drift”. 
IAV possess a single-stranded, eight-segmented RNA genome of negative polarity, which 
encodes the surface glycoproteins HA and NA and the M2 ion channel, that are all inserted into the 
viral lipid envelope; the matrix protein 1 (M1), that lies beneath the membrane; the three subunits 
(PB1, PB2, and PA) of the RNA polymerase complex, that is associated with the encapsidated 
genome; the nucleoprotein (NP), that coats the viral genome; and the nonstructural proteins NS1 
and NS2/NEP [2]. In addition, most IAV encode a nonstructural PB1-F2 protein of varying length, 
which has pro-apoptotic functions [3], and PA-x and N40, two newly identified proteins encoded by 
the PA and PB1 genes, respectively [4,5]. The IV replication cycle initiates with the attachment of 
HA to sialic acid (SA)-containing glycoprotein and glycolipid receptors on cell surface. The virus 
particle then enters the cell via clathrin-dependent endocytosis and macropinocitosis. Following 
entry, the acidic environment of the late endosome triggers a conformational change of HA which 
drives fusion of the viral envelope with the endosomal membrane. Moreover, the M2 protein creates 
a proton flow from the endosome into the virion leading to the dissociation of M1 from the viral 
ribonucleoprotein complexes (vRNPs). The released vRNPs are then transported into the nucleus, 
wherein the viral RNA polymerase initiates genome transcription and replication. Newly 
synthesized viral genome segments and proteins (PB1, PB2, PA, and NP) are complexed with M1 
and NEP and then exported from the nucleus to the cell membrane for the final assembly and 
budding phases. Finally, NA cleaves terminal SA residues from HA and the cellular receptors 
permitting the release of virions from the cell. In addition to the viral proteins, there are a number of 
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cellular proteins involved in each stage of IV replication, which could represent potential antiviral 
targets. 
The current options for influenza therapy include vaccination and two classes of antiviral 
compounds, the M2 ion channel blockers (adamantanes) and the NA inhibitors. However, vaccines 
need to be reformulated each year due to the genetic instability of the virus and are not always 
protective; thus, vaccination is unlikely to be effective against a rapidly emerging influenza 
pandemic. Adamantanes inhibit IAV replication by blocking virus entry. However, they have no 
activity against IBV and are often associated with serious side effects. NA inhibitors block the 
release of virions after budding from the host cell. They exhibit activity against both IAV and IBV 
but can also cause side effects. In addition, a major problem with both classes of drugs is the rapid 
emergence of drug-resistant viral strains which have limited the use of the NA inhibitors and 
rendered the M2 blockers ineffective. Thus, there is a clear need to discover novel IV inhibitors. 
The necessity of developing new drugs to overcome resistance and counteract threats of 
sporadic outbreaks of pandemic IAV has fueled the interest in gaining a deeper knowledge of the 
structures and functions of the viral components. The body of information coming out of new 
research initiatives may have the potential to be developed into useful therapeutic strategies. In 
addition, targeting of cellular factors involved in IAV replication represents a novel antiviral 
approach that could counteract viral drug resistance, as resistance against host-targeted antivirals 
would likely not emerge as rapidly as it is for virus-targeted inhibitors. In this review, we present an 
overview of recent progress in designing and developing new antivirals to block critical steps of the 
viral life cycle by inhibiting functions of viral proteins and/or host-virus interactions. 
 
New virus-based anti-influenza virus strategies 
In this section, we will discuss current and new anti-influenza approaches from the point of view of 
targeting the virus itself. A number of different novel virus-based anti-influenza strategies are being 
developed, which include improving currently available drugs in potency, spectrum of activity, or 
route of delivery; discovering new classes of compounds that target different viral proteins; and the 
application of combination therapy. An overview of the viral proteins/processes that are blocked by 
current drugs and by new inhibitors under development is depicted in Fig. 1. 
 
Antiviral strategies targeting the M2 ion channel 
Influenza M2 is a homotetrameric protein that acts as a proton channel [6]. After virus endocytosis 
into the host cell, M2 is activated in response to the low pH in the endosomal lumen and creates a 
proton flux from the endosome into the virion core [6]. M2 is essential for viral replication and its 
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short N-terminal extracellular domain is highly conserved in all human IAV [7]. For these reasons, 
M2 is considered an excellent target for antiviral agents. Indeed, the M2 protein of IAV (A/M2) is 
the target of two already licensed drugs for influenza treatment: amantadine and its methyl 
derivative rimantadine [8,9]. Both these adamantane derivatives bind the N-terminal channel lumen 
of the M2 pore and, upon binding, their charged amino group produces a positive electrostatic 
potential in the channel lumen, which involves an electrostatic repulsion of protons and prevents 
virus uncoating [8]. Unfortunately, these compounds are inactive against IBV, due to the fact that 
there are significant differences in the amino acid sequence between the A/M2 and the M2 of IBV, 
except for the H37xxxW41 sequence motif in the transmembrane domain required for the channel 
activity and proton selectivity [6]. Moreover, the rapid emergence of drug-resistant virus variants 
represents the main limit of these drugs. Indeed, almost all currently circulating IAV are resistant to 
amantadine and rimantadine, greatly limiting their utility in the clinical practice [10]. Thus, new M2 
blockers active against amantadine-resistant viruses are urgently needed. 
Drug-resistance to amantadine and rimantadine is associated to single or multiple amino 
acid substitutions at positions 26, 27, 30, 31, or 34 in the transmembrane region of A/M2 located 
outside of the H37xxxW41 motif [11]. More than 95% of the reported transmissible IAV carry the 
S31N mutation in the trans-membrane region of A/M2 [12,13]. For this reason, the possibility to 
target the predominant S31N mutant represents an attractive challenge. Recently, some small 
molecules were identified as potent inhibitors of the A/M2-S31N variant. Among these compounds, 
M2WJ332 exhibited an antiviral activity against the A/M2-S31N variant higher than that of 
amantadine against the wild-type A/M2 [14]. In addition to M2WJ332, some benzyl-substituted 
amantadine derivatives were recently found to inhibit the activity of both S31N and wild-type 
viruses [14]. Other frequent mutations in the A/M2 protein that confer resistance to amantadine and 
rimantadine are L26F and V27A [11,15]. Recently, novel small molecules with inhibitory activity 
against A/M2 bearing these mutations have been reported, including the spiroadamantane 9 [16], 
the spiran amine 8 [17], and some organosilane-based compounds [18]. In addition, a number of 
studies have reported other compounds (e.g., imines, adamantanaminoalcohols, adamantanamines, 
and spiro-piperidine) with inhibitory effects against the wild-type M2 protein more potent than 
amantadine; however, these compounds do not show any activity against amantadine-resistant 
variants [19-21]. Finally, a neutralizing antibody directed against the A/M2 ion channel, M2-7A, 
which is able to inhibit the replication of both amantadine-sensitive and amantadine-resistant 
viruses with similar IC50 values, has been identified [22]. Importantly, passive immunotherapy with 
M2-7A protected mice from a lethal IV challenge [22]. Although the exact mechanism of action of 
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M2-7A and its binding epitope have not yet been clarified, this inhibitor clearly deserves further 
investigation. 
To date, there is no single M2 blocker capable of targeting both wild-type IV and all 
circulating amantadine-resistant strains. Nevertheless, the therapy with a combination of these 
inhibitors could provide an effective strategy to solve the problem of amantadine resistance. 
 
Antiviral strategies targeting the neuraminidase 
An attractive target for the development of new anti-influenza drugs is provided by the viral 
neuraminidase. NA is a homotetrameric glycoside hydrolase that binds and removes a terminal SA 
residue to the adjacent oligosaccharide moiety of the cellular receptors recognized by HA, playing a 
key role in promoting IV infectivity (for a review see [23]). Indeed, NA is responsible for virus 
penetration through mucosal secretions, helping the virus to access to the target cells by mucus 
degradation [24]. Moreover, NA allows the detachment of the virion from infected cells and avoids 
the self-aggregation of progeny virions at late stages of infection by disrupting HA-SA interactions, 
thus promoting the release and spread of IV [23]. 
The proof-of-principle for the “druggability” of this target is represented by zanamivir 
(Relenza) and oseltamivir (Tamiflu) that are the first two inhibitors of NA licensed for the treatment 
of IAV and IBV infection [25,26]; however, the development and rapid spread of IV resistant to 
these drugs have limited their efficacy [27]. This has prompted the search for new anti-NA drugs. 
On the basis of the mechanism of action and the chemical features of the molecules, NA inhibitors 
can be distinguished into two groups: (i) synthetic analogues of SA and (ii) natural molecules and 
plant extracts with anti-NA activity. 
The mechanism of SA analogues is based on the competition with the natural substrate of 
NA, resulting in a block of the enzyme active site. These compounds are active against both IAV 
and IBV thanks to the fact that the NA active site is highly conserved among different NA subtypes 
of IAV and also among IBVs [28,29]. However, these inhibitors are effective against influenza 
infection only if administrated within 36-48 h of symptoms onset [29]. Zanamivir and oseltamivir, 
currently used worldwide as therapeutic and prophylactic agents against IAV and IBV, belong to 
this class. Zanamivir (GG167) is a 4-deoxy-4-guanidino analogue of SA and was the first approved 
NA inhibitor [26]. This compound is administrated in patients at least 7 years old via inhalation, 
due to its poor oral bioavailability (less than 20%) [30]. Although zanamivir is well tolerated and 
has few adverse reactions, the route of administration of this drug can represent a problem 
especially for children and elderly patients that could not be able to inhale zanamivir suitably [31]. 
To circumvent these issues, an intravenous formulation of zanamivir has been formulated and is 
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currently in Phase III clinical trial. Oseltamivir (GS4104) is an ethyl ester prodrug, which is orally 
administrated and is quickly converted into its active form oseltamivir carboxylate (GS4071) by 
hepatic esterases. Oseltamivir possesses higher bioavailability (around 80%) than zanamivir and can 
be administrated in patients ≥ 1 year old [32]. More recently, other two SA analogues, peramivir 
and laninamivir, have been licensed in some Asian countries and are currently under clinical 
evaluation in other countries. Peramivir (BCX-1812, RWJ-270201) is a cyclopentane compound, 
approved in Japan as Rapiacta and in South Korea as Peramiflu for use in adult and pediatric 
patients with IAV and IBV infection [33]; in addition, it is currently undergoing clinical trials in the 
USA and in other countries. This compound is administrated only as an intravenous formulation, 
due to its very low bioavailability [34]. Laninamivir (R-125489) is a SA analogue structurally 
similar to zanamivir. Laninamivir is administrated as octanoyl prodrug, laninamivir octanoate (LO; 
CS-8958, R-118958), and holds great promise for its long-acting inhibitory activity [35]. LO has 
been approved in Japan for clinical use (as Inavir) since September 2010, but is still undergoing 
clinical trials in the USA. 
Although the NA active site is a highly conserved target, a number of mutations in the NA 
of viruses selected in vitro in the presence of NA inhibitors and also in patients have been 
identified, namely substitutions of residues E105, E119, I122, Q136, D151, R152, D198, R224, 
S246, H274, R292, N294, and R371 [27]. These mutations map in framework or catalytic residues 
of NA and can directly or indirectly alter the shape of the active site structure, thus leading to lower 
efficiency in inhibitor binding ability [27]. Some mutations were found to confer resistance to 
certain NA inhibitors but preserve the susceptibility to others [27]; for example, the main mutation 
conferring resistance to oseltamivir (H274Y) also confers resistance to peramivir, but not to 
zanamivir [36]. In addition, due to the similar binding properties and chemical structures of 
zanamivir and laninamivir [37], it is expected that mutations causing resistance to zanamivir confer 
cross-resistance to laninamivir. Currently, no mutation associated with resistance to laninamivir has 
been identified and, although this finding remains to be confirmed, at the moment laninamivir 
remains the only NA inhibitor not subjected to drug resistance [27]. Based on NA crystallographic 
structure and knowledge of the binding mode in which these NA inhibitors interact with the enzyme 
active site [38], many other analogues of SA have been synthesized and characterized, in order to 
further optimize the binding properties of NA inhibitors. Work on novel anti-NA compounds 
obtained by structure-based drug design strategies is well summarized in other recent reviews 
[38,39]. 
An alternative and interesting approach to increase the efficacy of the approved NA drugs is 
provided by the use of multivalent inhibitors, by conjugating the compounds to a biocompatible 
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polymer [40,41]. Indeed, several reports showed that such multivalent presentation of NA inhibitors 
results in a dramatically higher antiviral potency than that obtained with the monomeric drug [41-
43]. As an example, zanamivir attached to the biodegradable polymer poly-L-glutamine exhibited 
an antiviral activity 1,000- to 10,000-fold higher than that of monomeric zanamivir [41]. In 
addition, a single dose of zanamivir dimers resulted in an in vivo longer-lasting activity against IV 
compared to monomeric zanamivir [43].  
In recent years, natural products have acquired increasing relevance in drug discovery, 
including as anti-influenza agents. Among natural products, many classes of compounds with 
promising anti-NA activity have been identified (reviewed in [44]); however, flavonoids are the 
most studied as NA inhibitors [44]. Flavonoids are a group of secondary plant metabolites 
containing 15 carbon atoms. In addition to antioxidant effects [45], they possess antiviral activity 
against a wide array of viruses, including IV [44], showing anti-NA activity [46-49]. In addition, 
plant extracts have also been evaluated for their inhibitory potential on NA, especially extracts from 
plants of traditional Chinese medicine [44]; however, often the mechanism of action and/or the 
active principle(s) have not been yet clarified [44]. As an example, a screening of extracts from 
many medicinal plants led to the identification of five plant extracts endowed with anti-NA activity 
in vitro and among these, the extract of Melia toosendan was found to be also active against IV in a 
mouse model [50]. 
 
Antiviral strategies targeting the hemagglutinin 
HA is a homotrimeric glycoprotein composed of a stem domain supporting a globular head. Each 
HA monomer consists of two disulfide-linked polypeptides, HA1 and HA2, derived from 
proteolytic cleavage of the single immature precursor HA0 by host proteases. The most part of HAs 
are activated by cleavage at a single arginine residue by extracellular proteases, whereas for other 
HAs, associated to highly pathogenic avian viruses, this cleavage is performed by furin-like 
intracellular proteases at sites characterized by multiple basic amino acids. HA is essential for the 
interaction of the virus to cells by binding to SA receptors on host cells and also it is involved in the 
low pH-induced membrane fusion between the viral envelope and the endosomal membrane [23]. 
A possible mechanism of inhibition of viral infection is to block the interaction between 
viral surface molecules and cellular receptors and the following fusion of the virion with the 
endosome membranes, thus preventing the entry of the virus into the host cell. Some drugs already 
approved for the treatment of human immunodeficiency virus (HIV) infection (enfuvirtide and 
maraviroc) and for the prevention of respiratory syncytial virus (RSV) infection (palivizumab) 
specifically act by interfering with this step of the viral life cycle [51-53]. In the case of IV, the 
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entry step can be blocked mainly by two strategies: i) by preventing the binding between the viral 
HA and the terminal SA of glycoproteins and glycolipids present on the cell membrane; ii) by 
blocking the process of fusion between the viral envelope and endosomal membrane, necessary for 
the release of the vRNP into the cytoplasm. 
As for the first strategy, a variety of antiviral agents have been reported that can interfere 
with IV attachment to target cells. These inhibitors can be divided in different groups based on 
chemical properties and their mechanism of action: 
1) Neutralizing monoclonal antibodies (mAbs) directed against the membrane-distal globular head 
domain of HA. The globular head of HA contains three receptor binding sites (RBS) and is 
responsible for the attachment to cellular receptors [23], thus representing the principal target of 
these inhibitors. The main limit of this antiviral strategy is the hyper-variability of the globular head 
of HA. In fact, several antibodies that target regions of globular head of HA, especially the exposed 
loops that surround the RBS, are typically able to neutralize a limited range of IVs, often showing 
strain-specific responses [54,55]. Despite the overall variability of the globular head of HA, the 
RBS is relatively conserved; thus, antibodies against this site possess a broader spectrum of 
neutralizing activity. An example is represented by CH65, which is able to neutralize several strains 
of IV in vitro, by inserting its heavy-chain CDR3 loop into the receptor-binding pocket [55]. Recent 
studies reported a few examples of RBS-directed antibodies with heterosubtypic anti-influenza 
activity. In particular, two mAbs, S139/1 and C05, showed neutralization activity against strains 
from multiple IV subtypes both in vitro and in mice [56,57]. Crystal structures of the antibody–HA 
complex confirmed that both antibodies are able to bind highly conserved residues in the RBS of 
HA [56,58].  
2) Decoy receptor or SA-containing inhibitors. This class of agents that can subdivided in: (i) 
polyvalent synthetic SA-containing inhibitors; (ii) natural inhibitors containing SA. Both these 
types of inhibitors act as receptor mimics and compete with sialylated receptors on the target cells 
for binding to HA and thus neutralize the virus attachment. In addition, their binding to the virion 
surface can lead to virus particle aggregation, causing a reduction of virus infectivity. As for the 
first type of inhibitors, the design of polyvalent synthetic SA-containing compounds has been 
proposed to overcome the low affinity of HA binding to monovalent SA analogues, which are 
considered ineffective in competing with the highly multivalent interactions between the virus and 
the host cell [59]. In fact, polyvalent SA-containing inhibitors were more potent in vitro than 
corresponding monovalent molecules [59]. Some of these molecules also exhibited protective 
effects against IV infection in mice [60,61]. As an alternative to multivalent sialosides, several 
groups have proposed the use of liposomes with SA analogues on the surface in order to allow a 
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multivalent presentation of SA [62-64]. The second type of inhibitors are constituted by SA-
containing natural molecules, such as glycoproteins or proteoglycans, which possess the ability to 
bind HA and at the same time to create a steric obstacle to the polyvalent interaction of the virus 
with cells, thus blocking the process of virus absorption to target cells. An example of these 
inhibitors is represented by the serum amyloid P component, which contains the α(2,6)-linked SA 
into the oligosaccharide side chains. This sialylated glycoprotein has been reported to limit IAV 
infection of airway epithelial cells and to have also therapeutic effects in mice [65]. 
3) Peptides against HA. Some peptides exhibiting potent and broad-spectrum anti-influenza activity 
recently emerged as inhibitors of viral attachment [66,67]. Similar to antibodies, these peptides 
specifically bind the HA protein and prevent IV absorption to the host cell. These peptides were 
found to be effective not only in vitro but also in vivo, even when administered post-infection. 
4) Carbohydrate-binding agents that recognize specific glycosylation sites on HA. The mechanism 
of action of these inhibitors exemplified by cyanovirin-N (CV-N). This protein, which derives from 
the cyanobacterium Nostoc ellipsosporum, recognizes high-mannose oligosaccharide structures on 
HA (oligomannose-8 and -9) and its binding to HA prevents virus adsorption to the cell [68]. In 
fact, removal of these glycans from HA causes a decrease of viral sensitivity to CV-N [68]. 
Interestingly, CV-N showed antiviral activity not only against IAV and IBV, but also against a 
broad range of enveloped viruses, such as HIV [69], Ebola virus [70], human herpesvirus 6 [69,70], 
and hepatitis C virus (HCV) [71]. The same mechanism seems to be used by a lectin from Green 
Alga Boodlea coacta (BCA) [72]. Indeed, BCA exhibited a strong inhibition of HA activity by 
specifically interacting with 1–2-linked mannose at the nonreducing terminus of HA [72]. In 
addition, BCA showed activity against HIV [72]. 
5) Natural molecules from plants. Finally, some natural molecules which interfere with the binding 
of HA to the cell surface have also been identified [73-76]. However, the molecular details of the 
mechanism of these compounds have not yet been elucidated. 
Another possible strategy of inhibition of viral entry consists in preventing the fusion of the 
viral envelope with the endosomal membrane, in order to avoid the release of virion components 
into the cytoplasm. There is a heterogeneous group of inhibitors that act at this step of the viral life 
cycle, with distinct mechanisms of action: 
1) Small molecules that inhibit the low pH-induced conformational change of HA. After binding to 
the cellular receptor, IV is internalized into endosomes by clathrin-independent endocytosis [77]. 
The low pH inside the late endosomes triggers an irreversible conformational change of HA and 
enables the extrusion of the fusion peptide and its consequent insertion into the endosomal 
membrane [78]. Several small molecules that bind pockets in the stem region of the native form of 
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HA have been identified as specific fusion inhibitors of IV [79-86]. Most of them prevent the 
fusogenic activity of the virus by blocking the low pH-induced conformational change of HA 
[79,81-86]. The most recent example of compounds acting by this mechanism is RO5464466, 
which stabilizes the neutral pH conformation of HA in a pre-fusogenic state and prevents the 
fusogenic change of HA [86]. In contrast, others compounds, such as C22, inhibit membrane fusion 
by destabilizing the structure of HA, resulting in a premature and ineffective conformational change 
[80,87]. However, these inhibitors possess common drawbacks that would severely limit their 
potential utility in the clinical practice. In fact, these small molecules show a high propensity to the 
emergence of drug-resistant variants and exhibit limited protection against different HA subtypes. 
An exception is represented by arbidol (ARB, 1-metyl-2-phenyl-thiomethyl-3-carbotoxy-4-
dimetylaminomethyl-5-hydroxy-6-bromoindolehydrochloridemonohydrate). In fact, ARB exhibits a 
broad spectrum of antiviral activity not only against IAV and IBV, but also against other viruses 
such as RSV, parainfluenza virus, coxsackie virus, rhinovirus, hepatitis B virus (HBV), and HCV 
[87,88]. This drug has been approved in Russia and in China for treatment and prophylaxis of IAV 
and IBV. Studies with viruses resistant to ARB bearing mutations which map in the HA2 subunit 
confirmed that ARB interacts with HA and acts by stabilizing its structure, thus preventing the low 
pH-induced fusogenic change of HA [89]. Recently, biochemical studies showed that ARB dually 
interacts both with cell membrane phospholipids and with aromatic residues of viral glycoproteins 
on the surface of enveloped viruses [90]. This mechanism of action of ARB can prevent the 
fusogenic change in viral glycoproteins required for membrane fusion and could explain the broad 
spectrum of antiviral activity of this compound.  
2) Neutralizing mAbs directed against the stem region of HA. Another possible approach to 
interfere with the fusogenic activity of HA is to develop mAbs directed against its highly conserved 
stem region, mostly formed by HA2 monomers. Thanks to the high conservation of this region, 
such a strategy could allow to overcome the problem of the high variability associated to the HA 
globular head. Recently, a number of studies reported antibodies that recognize conserved epitopes 
of the stem region of HA and show a broad antiviral activity against IAV both in vitro and in animal 
models [91-97]. One of these antibodies, CR9114, exhibited antiviral effects also against IBV both 
in vitro and in mice [92]. These observations suggest that the epitope recognized by CR9114 is 
highly conserved not only among the different IAV subtypes, but also among IBV and this finding 
opens the possibility to develop an universal influenza vaccine against IAV and IBV based on this 
epitope [92]. 
3) Broad-spectrum antivirals interfering with membrane fusion by a nonspecific mechanism. An 
additional approach is to block the fusion between virus and endosomal membrane in a step 
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subsequent to the conformational rearrangement of HA. High-molecular weight molecules can 
prevent the fusion between the virus and endosomal membrane by acting as a steric barrier. For 
their nonspecific - still not entirely clear - mechanism of action, these compounds are active against 
a wide range of viruses, including IV. Dextran sulfate and retrocyclin 2 represent two examples of 
this type of inhibitors. Dextran sulfate is a sulfated polysaccharide which exhibits inhibitory effects 
not only against IAV, but also against HIV, cytomegalovirus, herpes simplex virus (HSV), vesicular 
stomatitis virus, and RSV [98-100]. Thanks to its negatively charged sulfated/carboxyl groups, 
dextran sulfate interacts with HA, that has a net positive charge at pH ≤7 [101]. Biochemical studies 
highlighted that there is an inhibitory effect on membrane fusion only when dextran sulfate is added 
at early steps of the fusion process [102]. However, this compound does not seem to inhibit the low 
pH-dependent conformational change of HA, rather suggesting an inhibitory activity due to steric 
hindrance in the following step [102]. Other sulfated polysaccharides, such as iota-carrageenan and 
pKG-03 derived from the marine microalga Gyrodinium impudium, have been reported to possess 
anti-IV activity, although with an unknown mechanism of action [103,104]. Another broad-
spectrum antiviral that can be included in this class of inhibitors is retrocyclin 2. This molecule 
belongs to the family of theta-defensins and is able to inhibit not only IV, but also HIV and HSV 
[105-108]. Retrocyclin 2 was found to inhibit the process of membrane fusion even when HA is in a 
fusogenic conformation or when a state of membrane hemifusion is already induced [106]. Detailed 
studies on its mechanism of action demonstrated that retrocyclin 2 creates a network of crosslinked 
and immobilized surface glycoproteins both on the virus and on the host cell, thus blocking the 
successive membrane rearrangements necessary to complete the fusion process [106]. 
 
Antiviral strategies targeting the RNA polymerase  
The viral RNA-dependent RNA polymerase (RdRP) is a heterotrimer composed of subunits PB1, 
PB2, and PA, which carry out both mRNA transcription and replication of the viral genome. During 
transcription, in a process known as “cap-snatching” PB2 binds to the 5′ methyl cap of host pre-
mRNA molecules and PA, which has endonuclease activity, cleaves the pre-mRNA to produce a 
capped primer that is used to start transcription [109]. The PB1 protein possesses the RNA-
dependent RNA polymerase activity and it is also responsible for the addition of a poly(A) tail to 
viral mRNA. PB1 also catalyzes the genome replication, which occurs via a positive sense cRNA 
intermediate that is an exact copy of the vRNA [109]. The three polymerase subunits interact each 
other, in particular the N-terminus of PB1 interacts with the C-terminus of PA [110-112], while the 
C-terminus of PB1 binds the N-terminus of PB2 [110,113]; in addition, a weak transient interaction 
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has been proposed for PA and PB2 [114]. Thanks to its multidomain structure and multiple 
enzymatic activities, the RdRP can be targeted at different sites. 
While a number of nucleoside/nucleotide drugs have been developed against other viral 
polymerases and are commonly used for treating infections caused by HIV, HBV, and 
herpesviruses, very few compounds have been reported which target the polymerization activity of 
IAV RdRP. This is in part due to the fact that the RdRP active site of PB1 has not yet been 
structurally characterized and even the precise boundaries of this domain are not known. Almost 
twenty years ago, 2’-deoxy-2’-fluoroguanosine was described as an inhibitor of IV transcription, 
but it has not been further developed [115]. Ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-
carboxamide, RBV) is a nucleoside analogue that exhibits a broad antiviral activity against RNA 
and DNA viruses, including IV [116]. RBV is converted intracellularly into its monophosphate 
form, which inhibits the cellular enzyme inosine 5′-monophosphate (IMP) dehydrogenase, 
responsible for the conversion of IMP to xanthosine monophosphate during GTP synthesis, leading 
to inhibition of RNA synthesis [116]. The triphosphate form of RBV has been shown to interact 
with the IV RNA polymerase in a cell-free system [117]. However, despite evidence of in vitro 
antiviral activity of RBV against IAV RdRP, its clinical application for anti-influenza therapy has 
been rather limited, due to toxicity and poor in vivo efficacy. Indeed, variable results have been 
reported from clinical trials using oral or aerosolized [118] and intravenous [119] RBV for treating 
IAV- or IBV-infected patients. Thus, while RBV is currently approved for therapy against HCV and 
RSV, its clinical efficacy for the treatment of IV infection remains to be further investigated. In 
addition, an analogue of RBV - viramidine - was recently shown to have similar efficacy to RBV 
against IAV infections while exhibiting lower toxicity and thus may deserve further evaluation as a 
possible therapeutic agent [120]. Another anti-influenza nucleoside analogue is favipiravir (T-705; 
6-fluoro-3-hydroxy-2-pyrazinecarboxamide), which is a pyrazine derivative first identified in 2002 
[121]. T-705 was shown to inhibit influenza A, B, and C viruses in vitro and to be more effective 
than oseltamivir in protecting mice infected with IAV [121]. By cellular kinases, T-705 is converted 
to the active form, ribofuranosyl triphosphate, which acts as a nucleoside inhibitor of IV RdRP 
[122]. Remarkably, fapiravir does not inhibit the synthesis of cellular RNA or DNA and in contrast 
to RBV, it is not an effective inhibitor of IMP dehydrogenase, thus showing less cytotoxity than 
RBV [123]. T-705 is active against a broad range of IAV and IBV strains, including 2009 pandemic 
strains, highly pathogenic avian H5N1 viruses, and the recently emerged H7N9 avian virus, and it 
also inhibits influenza strains resistant to current antiviral drugs [123,124]. Besides IV, T-705 
inhibits a number of other RNA viruses, whereas it exhibits no inhibitory effect against DNA 
viruses. Importantly, very limited resistance to favipiravir has been reported [123]. A Phase III 
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clinical trial for evaluating favipiravir for influenza therapy began in Japan in October 2009 and has 
been completed, and two Phase II studies have been conducted in the United States since February 
2010 and the results are being reviewed [124]. In the near future, we may therefore see approval of 
clinical use of favipiravir for the treatment of influenza. 
Another possible strategy for selectively inhibiting IV replication is to target the 
endonuclease cap-snatching activity of the RdRP complex, which resides in the N-terminal region 
of PA [125,126]. In past years, a number of inhibitors (e.g., flutimide and L-735882) of PA 
endonuclease activity have been discovered by Roche, Merck, and other pharmaceutical companies 
using a structure-activity relationships (SAR) approach [127-129], but most of them have not been 
developed further. More recently, crystallographic studies revealed that the endonuclease active site 
of PA contains a conserved deep cleft which could be an excellent target for structure-based design 
of novel anti- IV drugs [125,126]. On this line, two groups reported co-crystal structures of the PA 
endonuclease domain with known or predicted inhibitors [130,131], providing insights that could be 
useful for the structure-based design of new PA inhibitors. In addition, a fragment screening using a 
high-resolution crystal structure of the N-terminal endonuclease domain of pandemic 2009 H1N1 
IV and structure-based optimization led to the identification of a hydroxypyridinone series of 
compounds exhibiting promising enzymatic inhibition; a compound from this series was also found 
to have a significant antiviral activity in cells [132]. Using a different approach, Iwai et al. screened 
33 different types of phytochemicals using a PA endonuclease inhibition assay in vitro and 
identified marchantins as PA inhibitors [133]. In particular, marchantin E docked well into the 
endonuclease active site and inhibited the growth of both AV and IBV.  
The cap-binding activity of PB2 might also be targeted by anti- IV agents. The crystal 
structure of the PB2 cap-binding domain (residues 318–483) bound to a 5′-cap analogue (m7GTP) 
[134] revealed a pocket in this domain of PB2 which could be a possible drug target. An m7GTP-
mimic, if developed, would inhibit the transcription of IV mRNAs, but most likely would also be 
recognized by cellular cap-binding proteins, thus posing significant selectivity and cytotoxicity 
issues. Another target for the development of anti-PB2 compounds may be the packaging signal at 
the 5’ end of the PB2 RNA. In fact, a recent study reported that a 15-mer phosphorothioate 
oligonucleotide derived from the 5’ end of the viral PB2 RNA, complementary to the 3’ end of its 
coding region (nucleotides 2279–2293), markedly inhibited IV replication [135]. However, the 
suitability of this type of inhibitors for in vivo anti-influenza therapy remains to be investigated. 
The interactions between the PA and PB1 as well as the PB1 and PB2 subunits have been 
shown to be essential for polymerase function [136,137]. In addition, the subunits binding interfaces 
are highly conserved between different viral strains [2]. Thus, inhibition of these interactions 
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represents an attractive strategy for the development of drugs with broad efficacy against all IV 
strains [138,139]. The feasibility of this approach was first proved by studies showing that short N-
terminal PB1 peptides, corresponding to the PA-binding domain of PB1, were able to block the 
activity of IAV polymerase and also inhibit viral replication [140,141]. Recently, two crystal 
structures of a truncated form of PA bound to a PB1-derived peptide have been published 
[142,143]. Importantly, these structures showed that relatively few residues drive binding of PB1 to 
PA, suggesting the potential for small molecule-mediated inhibition. On this line, an in silico 
screening of 3 million small-molecule structures using one of these crystal structures [142] led to 
the identification of two compounds (compounds 1 and 5) able to interfere with the interaction 
between PB1 and PA both in vitro and in cells, as well as transcription by the RdRP [144]. One of 
these molecules (compound 1) also inhibited the replication of a panel of IAV strains, including 
2009 pandemic strains and an oseltamivir-resistant isolate, as well as several IBV strains, with EC50 
values in the low micromolar range [144]. Interestingly, a compound, AL18, previously shown to 
inhibit subunit interactions of human cytomegalovirus DNA polymerase [145] was found to also 
block the PA/PB1 interaction as well as the replication of IAV and IBV [146]. In a similar, but 
more restricted screening, Fukuoka and colleagues performed a docking simulation using a drug 
database of ~4000 compounds and selected candidate compounds targeting the PA/PB1 interface 
[147]. Among these, benzbromarone, diclazuril, and trenbolone acetate exhibited anti-IAV activity. 
In addition, benzbromarone and diclazuril were shown to bind the PA subunit and to decrease the 
transcriptional activity of the viral RdRP. In a different approach, a total of 15,000 molecules were 
tested in an ELISA-based screening, which led to the identification of a benzofurazan compound 
that also showed inhibition of viral replication at micromolar concentrations [148]. However, both 
this compound and its derivatives exhibited significant cytotoxicity, thus likely excluding an in vivo 
use. Overall, the compounds targeting the PA/PB1 binding interface could provide the basis for the 
development of a new generation of therapeutic agents against IAV and IBV. 
The possibility of targeting other interaction sites in the polymerase complex, e.g., those 
between PB1 and PB2 subunit, recently emerged with the publication of the crystal structure of the 
PB1/PB2 binding interface [137]. The structure showed that only small regions of PB1 (residues 
678–757) and of PB2 (residues 1–37) are required for tight binding. Since the PB1/PB2 interface 
has a crucial function in regulating the polymerase complex and it is highly conserved among IV, it 
appears as a promising target for novel broad-spectrum anti-influenza drugs. As a proof-of-
principle, a synthetic peptide corresponding to residues 1–37 of PB2 was shown to inhibit the 
PB1/PB2 interaction in vitro [149]. However, to date no small molecule targeting this protein-
protein interaction has been yet reported, and indeed the flat PB1/PB2 interface may pose 
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significant challenges in developing a nonpeptide small-molecular-weight inhibitor. Recently, Li 
and colleagues reported that a peptide derived from amino acids 731–757 of PB1 can disrupt the 
interaction between the C-terminal part of PB1 (aa 676–757) and the N-terminal part of PB2 (aa 1-
40) and also inhibit viral RdRP activity and IV replication [150]. Surprisingly, the authors showed 
that this peptide interacts with PB1 rather than PB2. Furthermore, mutational analyses and 
computational modelling suggested that PB1731–757 peptide acts as a competitor of PB2 with respect 
to binding to PB1. Thus, the inhibitory mechanism of the PB1731–757 peptide is likely different from 
that of the interfacial peptides PB11–25 and PB21–37, which inhibit complex assembly by binding to 
its interaction partner PA or PB1, respectively, and could suggest new avenues for antiviral 
discovery. 
 
Antiviral strategies targeting the nucleoprotein  
Given the pivotal role of NP during the IV life cycle, it represents an emerging target for new 
antiviral approaches [100]. IAV NP orchestrates the vRNP assembly by covering the genomic RNA 
segments, facilitating the correct folding, and by directing the proper constitution of vRNP via 
protein-protein interactions with RdRP subunits. Oligomerization of NP into a trimer coating viral 
RNA is essential to maintain vRNP structure; however, IAV NP assembles into a trimer through 
monomer interactions independently from the presence of RNA.  
NP is a multifunctional, essential protein, which plays an active role not only in vRNP 
architecture, but also in transcription and replication of the viral genome and in vRNPs nuclear 
shuttling and cytoplasmic trafficking [7]. In the recent years, the interactions of NP with itself [151-
155], with viral RNA [156], with viral RdRP, or with cellular factors were exploited for the 
development of new anti-IV strategies, demonstrating the significant druggable potential of NP. As 
an example, short interfering RNA designed for NP gene silencing and possessing a 5’-triphosphate 
moiety to induce a RIG-I-mediated interferon (IFN) response exhibited potent inhibitory effects 
both in infected cells and in mice, demonstrating that NP knockdown is a successful strategy to 
inhibit IAV propagation [157,158]. Perhaps, the most promising feature of NP from a 
pharmaceutical point of view is the ability of self-interaction mediated by a flexible tail loop present 
in each monomer that inserts in the neighboring monomer. This interaction is stabilized by 
electrostatic interactions between E339 and R416 residues [154]. In addition, the phosphorylation at 
Ser-165 seems to regulate the polymerization status and RNA binding activity of NP in infected cell 
[159]. Small molecules able to interfere with correct protein-protein interactions between NP 
monomers were independently identified by different groups [151,153-155]; among these, 
nucleozin (NCZ) is the most studied. It is widely accepted that such compounds bind at least two 
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different sites on NP and act by either stabilizing monomeric NP or by inducing the formation of 
NP aggregates. The improper interactions of NP monomers occurring in the presence of these 
antiviral compounds interfere with the different functions of NP in the virus cycle. In fact, NCZ and 
its derivatives were reported to exert antiviral activity at different times of IAV cycle [160]: there is 
an early inhibitory effect of NCZ on viral RNA transcription and replication as well as a recently 
identified antiviral effect exerted on the cytoplasmic trafficking of newly synthesized vRNPs. NCZ 
is supposed to affect both the transport of vRNPs into the nucleus and, after nuclear export, the 
transport of newly synthesized vRNP through the cytoplasm that involves the cellular protein 
Rab11 [160]. Interestingly, also cellular proteins have been recently identified as restriction factors 
for IAV replication by interfering with NP oligomerization, such as cyclophylin E [161], or with the 
NP-PB2 interaction, such as the IFN-inducible Mx1 protein [162], thus highlighting NP interactions 
with both cellular and viral partners as potential targets of antiviral strategies. Finally, very recently 
naproxen, a clinically-approved inhibitor of inducible COX-2, was identified through a structure-
based in silico screening as the first inhibitor of the interaction between NP and RNA [156]. It was 
demonstrated that naproxen targets the RNA-binding groove of NP and blocks it in a monomeric 
form. Naproxen is effective against IAV H1N1 and H5N1 replication in infected cells and in mice. 
As prospected by the authors, the dual antiviral effect of this drug against IAV, i.e., inhibition of NP 
functions and of COX-2-induced pro-inflammatory response, could be particularly useful for the 
treatment of emerging pandemic IAV infections. 
 
Antiviral strategies targeting the Nonstructural protein 1 
NS1 is a multifunctional viral protein, whose major role is to antagonize the cellular antiviral 
response and in particular the IFN-mediated response [163,164]. Actually, NS1 IFN-antagonistic 
properties seem to be strain-specific [164]. NS1 subverts the cellular IFN response by different 
strategies: (i) it cooperatively binds to viral dsRNA [165], thus protecting it from the recognition of 
two cytoplasmic “sentinels” of viral infection, i.e., protein-kinase RNA-activated (PKR) [166] and 
2’-5’-oligo(A) synthetase (OAS)/RNaseL [167], which are activated by dsRNA and serve to shut 
off host protein synthesis (and also IFN pathway effectors) and to induce viral RNA degradation, 
respectively; (ii) it binds to cellular mRNAs processing factors, such as cellular polyadenylation 
specifity factor 30 (CPSF30) and polyA-binding protein II (PABP2) [168,169], thus inhibiting 3’-
mRNAs (such as IFN mRNAs) processing and nuclear/cytoplasmic trafficking; (iii) it interacts with 
the ubiquitin-ligase TRIM25 and blocks RIG-I activation, thus preventing subsequent IFN cascade 
activation [169]; (iv) it interacts with cellular IFN-inducible hGBP1 to antagonize its antiviral 
activity [170]; and finally (v) it targets IKK to block NF-kB activation [171]. NS1 post-translational 
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modifications such as phosphorylation and SUMOylation may modulate its activity and also the 
abundance of NS1 dimers and trimers in infected cells [172]. In fact, NS1 dimerization is essential 
for RNA binding, since mutations that block dimers formation also affect the RNA binding ability 
of NS1 [173].  
Taken together, NS1 represents an attractive target for new chemotherapeutic strategies, but 
to date no anti-influenza drug targeting this viral protein is under clinical development. However, 
some molecules were recently identified by a screen aimed at searching compounds that 
phenotypically suppress NS1 functions [174]. By this approach, 2,000 compounds were tested for 
their ability to suppress the slow-growth phenotype in yeasts expressing IAV NS1; four molecules 
able to restore normal growth in yeasts and also to inhibit IAV replication in cells were identified. 
These compounds and some derivatives showed anti-influenza activity only in IFN-competent cells, 
and the ability to reverse NS1-mediated block of IFN response [175]. One derivative, JJ3297, 
resulted to be dependent on cellular RNAseL functions for antiviral activity [176]. These 
compounds provide the proof-of-principle that NS1 activity can be blocked by small molecules that 
could be also used in combination with IFN agonists to enhance their antiviral therapeutic potential. 
Another target of NS1-based antiviral strategies recently reported is the interaction of NS1 with 
viral RNA. Indeed, compounds able to interfere with NS1/viral RNA binding have been identified 
both by in silico screening [177] and by high-throughput screening (HTS) developed to search for 
inhibitors of the binding of recombinant NS1 to a viral RNA construct in vitro [178]. By this 
combinatorial approach, three compounds able to effectively inhibit NS1 binding to RNA in vitro 
and to reduce the cytopathic effect of IAV in infected cells were identified. By another approach, 
i.e., a fluorescence polarization-based assay other inhibitors of the binding between IAV NS1 and 
dsRNA, a library of quinoxoline derivatives, and a large small molecule library were tested leading 
to the identification of a compound, epigallocatechine gallate, able to inhibit virus growth 
[179,180]. These compounds provide the proof that also the interference with NS1 binding to viral 
RNA could be a feasible anti-influenza strategy. On this line, also the dimerization of NS1 could 
represent an interesting target of new anti-influenza interventions; however, to date no compound 
that acts by this mechanism has been reported yet. 
 
Antiviral strategies using drug combinations 
Combination therapies that target multiple viral protein functions have been proposed to achieve 
greater antiviral effects than each compound given individually, reduce the development of drug-
resistance and administer lower drug doses, thereby decreasing adverse effects. Analogous to the 
treatments used against HIV and HCV, a combination of anti- IV drugs would be expected to be 
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more effective than single-agent chemotherapy in treating serious influenza cases. The combined 
use of amantadine + oseltamivir [181] and oseltamivir + T-705 [182] has shown therapeutic 
synergism in infected mice. In addition, association of oseltamivir and amantadine has been 
demonstrated to reduce the emergence of drug-resistant IAVs [183]. A preliminary, controlled 
clinical study comparing the therapy with rimantadine plus inhaled zanamivir versus rimantadine 
alone in hospitalized adult patients with serious influenza showed a higher efficacy for the 
combination of zanamivir with rimantadine [184]. Several other double-, triple-, even quadruple-
drug combinations could be envisaged for achieving additive or synergistic antiviral effects, based 
not only on the currently available drugs but also on new compounds under development. 
 
New host-based anti-influenza virus strategies 
IV replication is strictly host-dependent. In fact, a plethora of cellular proteins are engaged in each 
step of the virus life cycle have been identified as restriction factors, since their activities exert a 
dramatic effect on IV replication [185-187]. In recent years, several studies reported different 
experimental approaches aimed at identifying the cellular proteins that are essential for IV 
replication and could be potential targets of new antiviral strategies. Among these, there are for 
example genome-wide RNA interference screenings (reviewed in [188]), proteomic approaches 
[189], and yeast two-hybrid screenings [190,191]. Antiviral drugs targeting cellular functions are 
expected to have some advantages over inhibitors exclusively directed against viral targets, in 
particular for highly genetically unstable viruses such as IAV. In fact, inhibitors of cellular proteins 
and/or pathways should be less prone to induce the emergence of resistant strains; on the other 
hand, perturbing the cellular environment to disrupt viral functions could have adverse side-effects 
that should be carefully considered.  
Cellular proteins are found to be actively involved in virus attachment and entry, in 
endocytosis of the virus particle and subsequent uncoating, in primary viral RNA transcription and 
protein synthesis as well as in genome replication, and finally in assembly, budding, and release of 
new IV particles. From a pharmaceutical point of view, the host-virus interplay is highly 
challenging, since each interaction between viral and cellular partners virtually represents a 
potential antiviral target for the development of new drugs and therapeutic strategies.  
Here, we will discuss a series of new antiviral approaches based on the inhibition of cellular 
functions that have emerged as essential for IV replication. We will describe cellular proteins and/or 
pathways endowed with pharmaceutical potential due to their active engagement in IV cycle and 
some already identified small-molecular weight inhibitors that are currently under preclinical or 
 20 
clinical investigation as anti-IV agents. An overview of the cellular proteins/processes that could be 
targeted to block IV replication is illustrated in Figures 2 and 3. 
 
Antiviral strategies involving host factors that are engaged in virus attachment, entry, and release of 
virus particles 
As already mentioned above, the first step in the initiation of IV infection is the attachment of HA 
to SA-containing glycoprotein or glycolipid receptors on the host cell surface. An option for 
influenza therapy is the development of drugs targeting cellular components involved in this step 
rather than targeting the viral HA protein. The proteolytic activation of HA by cellular proteases is 
essential for IV propagation and may also represent an attractive antiviral target. Human airway 
trypsin-like protease (HAT), and transmembrane protease serine S1 members (TMPRSS) belong to 
the type II transmembrane serine proteases family expressed in human lungs and involved in HA 
activation. These proteases cleave some HAs of human IV strains with a monobasic cleavage site, 
in particular of H1, H2, and H3 strains [192]. TMPRSS2 cleaves HA intracellularly, while HAT 
cleaves HA at the plasma membrane; indeed, the cleavage by TMPRSS2, but not HAT, is resistant 
to certain protease inhibitors [193,194]. In addition, TMPRSS4 has been shown to be responsible of 
the activation of HA of 1918 H1N1 IAV, which caused the Spanish flu [195]. Protease inhibitors 
are thus potential anti-influenza agents [196]; in fact, some have been shown to suppress IV spread 
in cell culture [193], in animal models[197], and in humans [198]. IV propagation in HAT- or 
TMPRSS2-expressing cells the inhibition of HA cleavage was efficiently suppressed using specific 
low-molecular-weight peptide mimetic inhibitors [193,194]. The selectivity and potency of some of 
these peptide mimetic protease inhibitors were improved by incorporation of a synthetic amino acid 
residue, norvaline [199]. In addition, very recently a screening with the catalytic domain of 
TMPRSS2 and known trypsin-like serine proteases inhibitors identified a sulfonylated 3-
amindinophenylalanylamide derivative able to block IV propagation in human airway epithelial 
cells [200]. The soluble proteases secreted by lung epithelial cells, such as tryptase Clara [201], 
mini-plasmin [202], and ectopic anionic trypsin I [203] are involved in low pathogenic avian IV 
activation. Indeed, Kido et al. have shown that viral replication is inhibited in vitro and in infected 
rats by endogenous inhibitors of these enzymes, such as secretory leuko-protease inhibitor and 
pulmonary surfactant [196]. An inhibitor of serine proteases is aprotinin, a 58- amino-acid single-
chain globular polypeptide purified from bovine lung tissue. Aprotinin has a wide anti-protease 
spectrum and good physiologic tolerance in animals and humans [204]. There are various licensed 
formulations of aprotinin, including Trasylol, Gordox, Antagosan, and Contrycal [198]. Zhirnov et 
al. demonstrated that in the presence of aprotinin, IV prevalently contains uncleaved HA0 and the 
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resulting viral progeny is less infectious [205]. Aprotinin blocks IV replication in chicken 
embryonated eggs [206], cultured cells [194,195], mouse lung and heart [207], and airway epithelial 
cell cultures [208]. Other drugs similar to aprotinin, such as leupeptin and camostat and their 
nucleoside and nonnucleoside analogues, proved anti-IV activity [209]. Another circulating serine 
proteases inhibitor is 1-antitrypsin (AAT), a 52 kDa glycoprotein produced by the liver, also 
known as SERPINA 1 [210]. Independently of protease inhibition, AAT appears to possess anti-
inflammatory and tissue-protective effects, as well as antiviral activity especially against IV and 
HIV [210]. Finally, as mentioned above, the HA of some highly pathogenic IV strains, such as H5 
and H7 subtypes of avian IV [211], contains a multibasic cleavage site and are activated during the 
transport from ER to the plasma membrane by furin and other cellular proteases located in the trans-
Golgi network. Thus, the inhibition of furin or furin-like proprotein convertases may also represent 
an anti-IV strategy [212,213]. 
Another possible approach to block virus-host interactions is the removal of SA from the 
cellular membrane. Sialidases, that catalyze the removal of terminal SA residues from glycoproteins 
and glycolipids, have been demonstrated to be effective inhibitors of IV infection [214]. A novel 
drug currently in clinical development as a candidate inhibitor of influenza infections is DAS181 
(also known as Fludase), a recombinant fusion protein that prevents IV attachment by enzimatically 
removing SA receptors from the epithelial surface of the human airway [214]. DAS181 is 
composed of the catalytic domain of Actinomyces viscosus sialidase fused with the respiratory 
epithelium anchoring domain of human protein amphiregulin [215,216]. The advantages of A. 
viscosus sialidase with respect to other bacterial sialidases are broad substrate specificity, higher 
specific activity, and good tolerance by the human immune system [214]. Preclinical in vitro and in 
vivo studies demonstrated the inhibitory activity of DAS181 against various seasonal strains of IAV 
and IBV and prophylactic and therapeutic effects against H5N1 virus infection in mice [217,216]. 
Importantly, this compound is also effective against strains resistant to the existing antiviral drugs, 
for example against oseltamivir-resistant H1N1 clinical isolates [216]. Moreover, a recent phase II 
clinical study of inhaled DAS181 showed a significant decrease of viral load in influenza-infected 
patients [218]. 
The attachment of IV to the host cell membrane is followed by the internalization of viral 
particles via pH-dependent receptor-mediated endocytosis [219]. IV infection is in fact inhibited by 
lysosomotropic agents, such as ammonium chloride [220] and chloroquine [221]. IAV endocytic 
uptake is promoted by the activation of cellular receptors triggering signaling cascades, in particular 
the members of receptor tyrosine kinases (RTKs) family. A possible anti-influenza strategy is thus 
the inhibition of these receptors. Recently, Eirhoff et al. showed that the modulation of the 
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expression or the activity of epidermal growth factor receptor (EGFR) and c-Met receptor causes 
the alteration of IAV entry, suggesting the involvement of these receptors in the transmission of 
entry signals upon virus attachment [222]. In fact, a virus uptake reduction and consequently a 
decrease of progeny virus titer were observed upon treatment with small molecule inhibitors of 
tyrosine kinases (i.e., genistein, SU4312, picropodophyllin, and gefitinib), as well as by a specific 
EGFR and c-Met inhibition via siRNA [222]. 
The internalized influenza virions are trafficked along the endocytic pathway to acidic late 
endosomes [77]. Cellular ATP-dependent proton pumps, named vacuolar-type H+-ATPases 
(vATPases), mantain the acidification of endosomes, lisosomes, and Golgi-derived secretory 
vesicles in eukaryotic cells [223]. Selective inhibition of acidification of virus-containing 
endosomes could provide effective protection from viral infection [224]. On this line, Müller et al. 
reported the inhibition of IAV entry by the new vATPase inhibitor saliphenylhalamide (SaliPhe), a 
phenyl derivative of salicylihalamide A (SaliA), which exhibited a better antiviral effect/toxicity 
profile in comparison with various old generation vATPase inhibitors, such as concanamycin 
(ConmyA), bafilomycin A1 (BafA1), and archazolid (ArchB) [225]. Also in previous anti-influenza 
studies ConmyA and BafA1 were used as specific potent blockers of vATPase activity, but their 
pharmacological use in vivo as antivirals resulted incompatible because of their toxicity in animals 
[226]. The target of BafA1, ArchB, and ConmyA is the subunit c of the V0 domain of vATPase 
[227,228]. The new generation vATPase inhibitors with reduced toxicity probably target a different 
binding site of the proton translocation domain with respect to older inhibitors [225]. Recently, 
other small molecules, e.g. the natural compound diphyllin, have also been shown to prevent IV 
entry by inhibiting vATPases [229]. 
Many essential cellular processes are regulated by the ubiquitin-proteasome system (UPS), 
an important intracellular protein degradation pathway. Different studies reported that the UPS is 
involved in IAV replication cycle and UPS inhibitors impair viral growth. A study by Khor et al. 
showed that treatment of infected cells in vitro with the proteasome inhibitor MG132 drastically 
reduced IV infectivity by blocking the virus entry process but not virus replication and budding 
[230]. In the presence of MG132, virus particles resulted trapped into endocytic compartments 
distinct from the classical early and late endosomes [230]. Widjaja and coworkers investigated the 
role of the UPS in IAV entry and replication using MG132 in combination with BafA1 and the 
E36ts20 hamster cell line [231], which expresses a temperature-sensitive E1 [232]. The results 
showed that IAV RNA synthesis depends on UPS; indeed, the inhibition of the proteasome affected 
IAV RNA synthesis and consequently viral protein expression. Actually, the mechanism of 
inhibition of IAV RNA synthesis by proteasome inhibitors is still unknown. The experiments 
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performed with MG132 combined with BafA1 showed that these proteasome inhibitors affect IAV 
replication at a post-fusion step. A possible mechanism of antiviral activity of proteasome inhibitors 
might be interference with the disassembly of viral particles and subsequent uncoating, resulting in 
retention of the vRNPs in the cytoplasm [231]. Also studies with the FDA-approved proteasome 
inhibitor PS-341, a dipeptidyl boronic acid also known as bortezomib or velcade, revealed anti-IV 
activity [233]. The inhibition of the activation of NF-κB pathway as a consequence of the lack of 
IκB degradation was suggested as another possible explanation of the antiviral effect of proteasome 
inhibition. In addition, a new proteasome inhibitor, VL-01, was shown to inhibit IAV replication in 
vitro in A549 cells infected with H1N1 and H5N1 IAV strains and in infected mice when 
administered by aerosolic route, as well to reduce the systemic pro-inflammatory cytokine and 
chemokine release [234]. For these reasons, although the mechanism of action of protesome 
inhibitors against IV is not yet completely clear, this class of compounds deserves further 
investigation as possible new anti-influenza drugs. 
 
Antiviral strategies involving host factors that are engaged in vRNP nuclear trafficking, viral RNA 
transcription/replication, and processing 
Viral RNA synthesis, which entails both primary mRNA transcription and vRNA replication 
processes, is directed by the virus-encoded RdRP, either transported into the nucleus directly after 
viral entry or de novo synthesized in the infected cell. The initiation of primary mRNA transcription 
also depends on the activity of host RNA polymerase II (RNAP-II) and other accessory factors such 
as the positive transcription elongation factor 1b (pTEF1b), which consists of the cyclin-dependent 
kinase 9 (Cdk9) and Cyclin T1 complex [235]. In uninfected cells, pTEF1b promotes the switch 
from transcription initiation to elongation step by phosphorylating the C-terminal domain (CTD) of 
the largest subunit of RNAP-II at Ser-5. Active pTEF1b is recruited for the replication of different 
viruses, including IV, for which it was demonstrated that pTEF1b interacts with viral RdRP 
complex, thus facilitating its association with host RNAP-II and the cap-snatching process [236]. 
The cellular RNAP-II in the “initiating status”, when associated with a nascent pre-mRNA, is 
essential for viral mRNA transcription. In fact, there is a physical interaction between viral RdRP 
and hyperphosphorylated CTD of RNAP-II that results in cap-snatching by PB2 and cleavage of the 
5’-end of cellular pre-mRNA by PA. Since siRNA-mediated knock-down of cyclin T1 resulted in 
strong inhibition of viral transcription and replication, while the enzymatic activity of Cdk9 was not 
required, Zhang and colleagues hypothesized that, to enhance viral transcription, pTEF1b might 
function as an adaptor to facilitate the association between viral RdRP and stalled cellular RNAP-II 
[236]. On this line, inhibitors of RNAP-II, such as α-amanitin and actinomycin D, also inhibited IV 
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replication [237]. Furthermore, 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole, an inhibitor of 
Cdk9 that prevents elongation catalyzed by RNAP-II, was reported to block IV replication [238]. 
However, the potential of CyclinT1/Cdk9 as an anti-influenza target should be more deeply 
investigated, given the raising interest on the role of pTEF1b in many pathogenic processes, 
including HIV replication, and the number of inhibitors that are under clinical investigation as 
potential antiretroviral drugs [239,240]. The interacting portions of viral RdRP and pTEF1b remain 
to be yet identified. The identification of the residues essential for their interaction could prompt the 
design of protein-protein interactions (PPI) inhibitors, similar to the cyclin T1-derived peptides with 
anti-HIV activity [241].  
Not only the cellular transcription machinery but also polyadenylation and splicing factors 
are involved in viral mRNA processing. As already mentioned, NS1 specifically interacts with 
cleavage and CPSF30 and PABII to achieve optimal viral mRNA processing [242,243]. In 
particular, given the essential nature of the NS1/CPSF30 interaction for IV replication, it has been 
proposed as a potential target of antiviral strategies based on PPI disruption [243]. The same 
strategy could be applied once the interactome of viral RdRP and other viral and cellular proteins 
will be fully dissected and PPI essential for IV productive replication will be identified. For 
example, six cellular proteins that functionally interact with RdRP have been recently identified as 
host factors essential for RdRP activity [191]. RNAP-II is also required for nuclear export of certain 
viral mRNAs [244], thus also this additional activity of cellular RNAP-II in IV life cycle might 
represent a potential target for novel host-based antiviral strategies. 
The nuclear translocation of vRNP components to promote new vRNP assembly and export 
depends on a number of host factors such as importins and molecular chaperones that may represent 
antiviral targets less prone to raise resistant viruses. In particular, the Hsp90 protein plays a key role 
in the nuclear translocation of vRNP components PB1 and PB2, by forming a PB1-PB2-Hsp90 
complex prior to the assembly of the RdRP complex [245]. Inhibitors of Hsp90, such as 
geldanamycin and 17-AAG, affect IV replication in cell culture possibly by blocking the nuclear 
import of PB1 and PB2 and by inducing their degradation [246]. Other host factors representing 
possible antiviral targets are proteins involved in the nuclear export of vRNP. For instance, the 
interaction between nucleoporin Nup98 and viral NS2, also called viral nuclear export protein 
(NEP), has been reported [247]. The GLFG repeat domain of Nup98 has a transdominant effect on 
Nup98/NS2 and blocks virus propagation [247], suggesting that this interaction could be a target of 
an antiviral strategy based on PPI disruption. Also leptomycin B, which is a specific inhibitor of the 
binding of chromosome region maintenance 1 protein (CRM1)/Exportin complex to nuclear export 
signals, blocks IAV vRNPs nuclear export in infected cells [248]. Thus, vRNPs nuclear export is 
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CRM1 pathway-dependent and is potentially susceptible to inhibition by small molecules. Very 
recently, other specific nuclear export inhibitors of natural origin, valtrate and 1-acetoxychlavicol 
acetate, that target cellular CRM1 have been reported to be potent inhibitors of IAV replication in 
infected cells [249]. The cellular protein Hsc70 is also involved in the regulation of the nuclear 
export (but not import) of vRNPs, via an interaction with viral M1 protein. The nuclear export of 
Hsc70 is also blocked by leptomycin B; thus also this host factor could represent a possible antiviral 
target [250]. Very recently, the serum- and glucocorticoid-regulated kinase 1 (SGK1) has been 
identified as essential for IAV replication in A549 cells [251]. By using siRNA-mediated 
knockdown and pharmacological inhibition, it was demonstrated that SGK1 is involved in vRNPs 
nuclear export and that a specific SGK1 inhibitor, GSK 650394, is able to block IAV replication in 
A549 cells. Thus, inhibition of SGK1 may represent another anti-IV strategy. 
 
Antiviral strategies involving host signaling pathways 
Many host cell signaling pathways are affected during IV infection; among these there are the 
mitogen-activated protein kinase Raf/MEK/ERK pathway, the phophatidylinositol-3-
kinase/Akt/mTOR pathway, the protein kinase C (PKC) pathway, the NF-κB pathway, and a more 
recently identified inositol-requiring enzyme (IRE) stress pathway. The activation of host signaling 
pathways is essential for productive IV infection, since small molecules that inhibit any step of 
signal transduction are also able to block virus propagation by affecting different events in IV life 
cycle as it will be described below. 
The mitogen-activated protein kinase (MAPK) signaling pathway is activated in response to 
a variety of stimuli, such as mitogenic factors, oxidative stress, inflammatory cytokines, and 
morphogenic stimuli. This pathway is mainly constituted by a tripartite module effectors consisting 
of a series of protein kinases that activate the downstream effectors by phosphorylation [252]. There 
are three principal MAPKs pathways depending on the stimuli, effectors, and response. It is mainly 
accepted that the extracellular-regulated kinase (ERK) module is activated by mitogenic stimuli and 
leads to cell proliferation; the JNK/p38 module is activated by oxidative stress, inflammatory 
cytokines, and other stimuli and leads to apoptosis and inflammation; and the ERK5 module is 
activated by morphogenic stimuli [252]. IV is known to activate all the MAPKs pathways and the 
inhibition of this activation has a detrimental effect on virus replication [253]. The phosphorylating 
activity of MAPKs pathways effectors plays a major role in vRNP trafficking, particularly in NEP-
mediated vRNP nuclear export, and in viral infectious particle production [254-256]. Of particular 
interest, MAPKs inhibition can be obtained both pharmacologically (by using inhibitors) and by 
restoring the physiological reduced state of intracellular environment of the infected cells after the 
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oxidative stress caused by IV infection [257]. In fact, MAPKs pathway, like other cellular signaling 
pathways activated by IV, such as PI3K and NF-κB-mediated signaling, is strictly dependent on 
host cell redox state [258-260]. On this line, MAPKs inhibitors that can block IV replication and the 
pro-inflammatory cascade are represented by kinase inhibitors, such as the MEK-specific inhibitor 
UO126 [261,262,253], and antioxidant compounds, such as p38 inhibitor SB203580 and N-
acetylcysteine [263,264], glycyrrizin [265], glutathione and its derivatives [266,267], and curcumin 
and resveratol derivatives [268]. All these compounds are potential new host-based anti-influenza 
drugs that could be used in combination with “old” anti-influenza drugs such as oseltamivir, as 
prospected in [269].  
PKC plays a role at different stages of IAV replication, in particular in virus entry. In fact, 
the binding of viral HA to the host cell activates PKC signaling [270] and, according to this, the 
PKC signaling inhibitors bisindolylmaleimides block viral entry possibly at the stage of post-fusion 
endocytosis [271,272]. Furthermore, also the viral M1, PB1-F2, and NS1 proteins are substrates of 
PKC [273-275]. In keeping with the importance of PKC signaling during IV infection, the block of 
its activation or the treatment with specific inhibitors affect not only virus entry [272] but also 
vRNP trafficking [273] and viral propagation [276]. 
The redox state of the infected cell also influences other two important processes in the IV 
life cycle, i.e., HA maturation and NF-kB activation. HA is a disulfide-rich protein and is initially 
found as a glycosylated monomer in the endoplasmic reticulum (ER). Then it undergoes 
trimerization, oxidation catalyzed by the cellular protein disulfide isomerase (PDI), cleavage, and 
finally is inserted into the plasma membrane. The activity of PDI is enhanced by the oxidative 
environment produced by IV infection. Thus, compounds that are able to restore the cellular redox 
state, such as glutathione, are also able to exert antiviral activity by two distinct mechanisms: (i) by 
interference with the activation of redox-sensitive signaling pathways exploited by the virus, such 
as MAPKs and PI3K pathways and (ii) by blocking the maturation of viral HA protein [257,256]. 
Also thiazolides are potential broad-spectrum antivirals that exert anti-influenza activity by 
blocking HA terminal glycosylation and impairing the trafficking of HA precursors from ER to 
Golgi [277]. However, the exact mechanism of action is still to be elucidated, although a cell-
mediated effect of thiazolides has been postulated due to the observed inhibition of different viruses 
by this class of molecules.  
The redox-sensitive signaling pathway of phosphoinositide 3-kinase (PI3K)/Akt/mTOR is 
also activated by different extracellular stimuli and by IV infection. Its activation transduces the 
transcriptional signal through a phosphorylation cascade of other downstream kinases such as 
Akt/PKB, cAMP-dependent kinase (PKA), and ribosomal S6 kinases and mTOR. The role of PI3K 
 27 
pathway activation during IV infection is still controversial. There is increasing evidence that either 
pro-viral or anti-viral effects following PI3K pathway activation might be dependent on the stage of 
virus cycle at which activation occurs, as well as on the viral strain and the spatial localization of 
kinase effectors [164,278,279]. The IV NS1 protein is known to bind PI3K [280] and this 
interaction could play a role in the activation of NF-κB activation and pro-inflammatory cascade 
and anti-apoptotic signaling; however, other viral factors could contribute to PI3K pathway 
activation. Thus, there are still a number of unresolved questions about IV and PI3K pathway 
interplay [281]. Recently, a role for PI3K and ERK activation in virus entry was reported, since the 
early activation of both kinases stimulates acidification of the intracellular environment induced by 
the vATPase and the internalization process [255]. The key role of the activation of PI3K pathway, 
although still a little fuzzy, is mirrored by the evidence that compounds targeting PI3K or 
downstream effectors, such as PI3K inhibitors wortmannin [282] and LY294002 [283], or mTOR 
inhibitors [284] block IAV replication in vitro. For this reason, considering the increasing 
availability of PI3K/Akt/mTOR inhibitors already approved or under clinical investigation as 
anticancer drugs [285], the inhibition of this host cell pathway as a new anti-influenza approach 
clearly deserves further investigation. Finally, very recently the small molecule multi-kinase 
inhibitor ON108110 was reported to reduce the IAV replication by restricting viral RNA synthesis 
[286]. 
Another pathway targeted by IV infection is that of NF-κB, a family of transcription factors 
that play a role in induction of inflammation, activation of immune response, proliferation, and 
apoptosis [287]. The activation of NF-κB pathway is critical for IV productive replication [288-
290] and is the result of the ability of viral HA, NP, and M1 proteins to produce oxidative radicals. 
The oxidative stress activates redox-sensitive signaling pathways and the NF-κB inhibitor IκB 
kinase (IKK), which is responsible of its derepression and transcriptional activation [291]. The 
essential nature of active NF-κB for IV replication makes it a promising target of antiviral 
strategies. On this line, a number of inhibitors of NF-κB activation, such as acetylsalicylic acid 
[288], SC75741 [292], BAY 11-7082 [293], pyrrolidine dithiocarbamate [294], as well as 
antioxidant agents (see above and [295]), have been reported to block IV replication and 
propagation. 
Recently, the unfolded protein response (UPR) pathway, which is activated upon ER stress 
[296], has also been proposed for new host-based anti- IV strategies. The UPR pathway is activated 
in the case of increasing protein misfolding induced by ER stress. The high presence of misfolded 
proteins in the ER induces UPR activation, upregulation of chaperones transcription, the decrease of 
cellular mRNA transcription, and the increase of ER-associated proteasomal degradation of 
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unfolded proteins. Inositol-requiring enzyme 1 (IRE1) is involved in the latter process and is also 
the only UPR pathway branch activated by IAV infection [296]. IRE1 possesses both kinase and 
endoribonuclease activity and is able to activate the MAPKs signalling and to activate, by favouring 
its unusual splicing, the transcription factor XBP1 involved in ER-associated protein degradation. 
Inhibition of IRE1 activation by chemical chaperones that alleviate ER stress or its enzymatic 
inhibition by small molecule compounds also block IAV replication, thus opening a new therapeutic 
intervention option by targeting a host cellular mechanism; however, possible off-target effects 
related to the inhibition of the cellular UPR pathway should also be carefully considered [296]. 
The cellular cyclooxigenases (COX) pathway is also engaged during IV infection, in 
particular in the case of human infection with highly pathogenic avian strains such as H5N1 [297]. 
In fact, the H5N1 strain strongly upregulates COX-2 during the infection of human macrophages, 
and COX-2 mediated pro-inflammatory signaling could be responsible of the hypercytokinemia that 
distinguishes the pathogenic mechanism of H5N1 strain in humans. Recently, it was demonstrated 
that the non-steroidal COX-2 inhibitor nimesulide is able to inhibit H5N1 strain replication in 
human macrophages; thus, also COX-2 could represent a promising cellular target for new anti- IV 
strategies [298].  
In conclusion, there is increasing evidence that understanding the molecular mechanisms 
underlying how IV modulates the host cell signaling pathways could be the key that opens the door 
to innovative therapeutic antiviral strategies.  
 
Antiviral strategies involving host cell metabolism 
IV uses cellular constituents to produce its own viral RNAs, proteins, and lipid envelope. However, 
the virus needs to purchase dNTPs, amino acids, and membrane components from the host cell and 
the best way is to induce the degradation of host nucleic acids, proteins, and organelles to obtain 
new building blocks to be recycled in the synthesis of viral components. Autophagy is a 
physiological process aimed at self-renewal and recycling of cellular constituents and consists of 
degradation of organelles and proteins that occurs into lysosomes; however, it can be induced by 
various stress conditions and by infection with certain viruses, including IV, through the inhibition 
of the mTORC1 pathway [299]. The mTORC1 inhibition, obtained either pharmacologically or 
under stress conditions, results in the activation of the so-called autophagy-related genes and in 
autophagosome biogenesis. However, it is still matter of debate whether IV really induces 
autophagy or if autophagy is just a consequence of the perturbation of cellular pathways and 
homeostasis induced by IV infection [299]. Waiting for answers to the high number of open 
questions, the presumed IV-induced autophagy is an emerging target of new antiviral strategies. 
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Indeed, two molecules recently identified by cell-based screenings, i.e., procyanidin and 
evodiamine, were able to block autophagy and also IAV replication in infected cells [300,301]. 
Other cellular proteins recently have emerged as host restriction factors and highlight the strict 
interplay with viral proteins, particularly NS1. This is the case of REDD1 protein, a major negative 
regulator of the mTORC1 pathway, whose expression is increased by the treatment with 
naphtalimides, antiviral compounds that are able to antagonize NS1 and thus to reduce IV 
propagation [302].  
The degradation of cellular nucleic acids is not the only strategy whereby IV enriches the 
dNTPs pool for viral RNA synthesis [303]; in fact, also de novo synthesis of pyrimidine and uracil 
salvage pathways are engaged during IV infection, depending on the cell type [304]. Pyrimidines 
are important precursors used for RNA (uracil and cytosine), glycoproteins, and phospholipids 
biosynthesis. On this line, compounds able to deplete the cellular pyrimidine pool show anti-
influenza activity. An example is the small molecule A3, identified by HTS, which possesses broad-
spectrum antiviral activity by targeting pyrimidine metabolism and in particular the mitochondrial 
enzyme dihydroorotate dehydrogenase (DHODH) [304]. This enzyme is an antiviral target of other 
two antiviral drugs, i.e., leflunimide and brequinar [305]; however, the authors hypothesized a 
different mechanism of action for A3. DHODH has emerged as a possible anti-IV target of another 
class of inhibitors, the quinolone carboxylic acid derivatives, which were reported to inhibit IAV 
replication in infected cells [306]. Furthermore, by studying their effects on DHODH inhibition, it 
was demonstrated that DHODH block leads to the up-regulation of cellular antiviral factors, such as 
the NXF1 protein, which is able to reverse the cellular mRNA export block mediated by viral NS1 
protein [306]. However, de novo pyrimidine synthesis requirement for efficient viral replication 
may be cell- and species-specific, since it was reported that the nonnucleoside DHODH inhibitor 
D282 showed anti-IAV and IBV activity in vitro but not in infected mice [307].  
Lipid mediators and lipid metabolic pathways are also involved in IV infection. Very 
recently, it was reported the identification of a potent IV replication inhibitor identified by a 
screening using derivatives of omega-3 polyunsaturated fatty acid (PUFA) [308], which are 
biosynthetic precursors of lipid mediators with anti-inflammatory and pro-resolving properties 
[309]. The omega-3 PUFA-derived lipid mediator protectin D1 (PD1) is able to potently inhibit 
IAV replication in vitro and in infected mice also at late stages of infection [308]. Furthermore, it 
was demonstrated that its mechanism of action specifically involves the impairment of viral 
transcripts nuclear export mediated by the cellular protein NXF1, without significant effects on 
cellular mRNA export or antiviral response. Thus, the further clinical development of PD1, given 
its potency and late-stage efficacy, is strongly encouraged.  
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Not only lipid soluble mediators, but also lipid metabolism has been involved in IV 
infection, since it was demonstrated that budding and release of new virus particles occur at specific 
domains of the plasma membrane, called lipid rafts [310]. Lipid rafts are dynamic microdomains of 
the cell membrane characterized by a higher percentage of cholesterol, sphingolipids, and 
phospholipids containing saturated fatty acids; this particular composition makes lipid rafts 
extremely flexible. IV HA and NA proteins are recruited at these specific domains, together with 
other cellular proteins responsible of vesicle formation, thus they are considered to be the sites of 
budding initiation [310]. It was reported that cholesterol depletion [311] or the expression of an 
IFN-inducible cellular protein, viperin [312], disrupt plasma membrane by perturbing lipid raft 
formation. Viperin interacts with and inhibits farnesyl diphosphate synthase (FPPS), a cellular 
enzyme involved in the synthesis of various isoprenoid-derived precursors of cholesterol and other 
essential cellular components [312] Furthermore, inhibition of FPPS, either by siRNA or by viperin 
expression, also inhibits IAV release and replication by perturbing lipid raft correct formation 
[312]. These findings suggest that perturbing membrane fluidity and/or composition could be a new 
host-based anti-influenza strategy. The recent identification by in silico screenings of new FPPS 
inhibitors, beside traditional bisphosphonate FPPS inhibitors, opens new avenues for further 
investigation of the potential anti-influenza activity of FPPS inhibitors, which are already under 
clinical investigation as anti-cancer and anti-infective agents [313,314]. In keeping with the 
importance of membrane composition for efficient IV replication, the inhibition of cellular 
sphingolipids biosynthesis has also been reported to have an abortive effect on the replication of 
IAV and IBV and to perturb the intracellular distribution of viral HA protein [315]. Very recently, 
also the biosynthetic pathway of sphingomyelin was reported to be essential for the intracellular 
transport of viral glycoproteins; thus, its modulation could also represent a possible antiviral 
strategy [316].  
 
Antiviral strategies involving host cell antiviral response 
Infection of ssRNA viruses, including IV, is known to be recognized by certain cellular pattern 
recognition receptors (PRRs), such as transmembrane Toll-like receptors (TLR) 3, 7, and 9, and 
cytoplasmic RIG-I like receptors (RLRs), which sense the invasion of a pathogen and counteract it 
both by stimulating an intracellular antiviral state and by sensitizing neighboring cells. One of the 
most important cellular defense strategy against IV infection is the activation of type I and III IFN 
pathway [317]. Type I IFN expression is the result of the PRRs activation and downstream 
signaling and leads in turn to the activation of more than 300 IFN-stimulated genes , whose 
products cooperate to inhibit IV replication at different stages, to trigger the adaptive immune 
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response, and ultimately to induce apoptosis of the infected cell. IVs have evolved various strategies 
to evade IFN response (reviewed in [317]) with NS1 representing the major player (see above). 
Given the pivotal role of IFN pathway in the early anti-influenza cellular response, its 
activation or enhancement represent an important option for antiviral intervention. Small molecules 
that act as agonists of TLRs and RLRs are able to induce IFN and other pro-inflammatory cytokines 
and chemokines, as well as to function as vaccine adjuvants. Indeed, treatment with poly(I·C), CpG 
oligodeoxynucleotides (ODNs), and other TLRs ligands proved to be effective in protecting aged 
mice against lethal IAV infection. Recently, a cell-based HTS aimed at identifying small molecules 
able to induce IFN was reported [318]. The lead compound 3 identified by this HTS is able to 
induce an IFN-dependent antiviral state that cannot be counteracted by IAV NS1 protein [318]. 
Furthermore, a novel small molecule, ASN2, which inhibits viral RdRP subunit PB1 was reported 
to have additional IFN-inducing properties [319]. ASN2 was identified by a cell-based HTS aimed 
at identifying molecules able to activate luciferase expression under control of INF-β promoter and 
is an effective inhibitor of IAV replication both in infected cells and in mice. The IFN-inducing 
properties are most likely due to the ability of ASN2 to inactivate PB1 and therefore to the loss of 
NS1 expression [319]. Also the treatment with high-molecular-weight poly-γ-glutamate (HM-γ-
PGA) produced by a bacterium from Bacillus sp. was reported to induce IFN response and to exert 
potent inhibition of highly pathogenic IAV infection in humanized mice [320]. Short synthetic 
RNA molecules with an exposed 5’-triphosphate moiety are substrate for RIG-I and were reported 
to be able to induce a potent antiviral response that results in inhibition of IAV replication in A549 
cells and also to protect mice from lethal IV infection [321].  
In conclusion, the induction of IFN antiviral response by small molecules or polymers is 
another promising strategy for the development of new anti-influenza drugs that could be used in 
combination with other already available drugs to enhance their efficacy and to counteract 
synergistically the viral infection.  
 
Concluding remarks 
Infection with IV is a life-threatening event for high-risk patients, such as the elderly and patients 
with cardiovascular, pulmonary, or renal diseases, diabetes, and immunodeficiency, but also for the 
whole human population. The IV disseminate rapidly around the world, and how and when new 
IAV emerge as pandemic strains and their mechanism of pathogenesis are still poorly understood. 
The virus changes very quickly, humans have no natural immunity to it and infected birds may be 
able to transmit it before they show symptoms. Any virus with these characteristics could devastate 
the human population while causing massive economic and social chaos. The last - but not least - 
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emerged avian highly pathogenic IAV to be reported is the H7N9 virus, which is a new reassortant 
of avian origin isolated in China and associated with severe respiratory disease with 40% of 
mortality [322]. To date, this virus represents a major concern, since it might be able to become 
pandemic [323]. Besides vaccination, treatment with M2 ion channel blockers and NA inhibitors is 
currently the only option for influenza management. However, these weapons are clearly 
insufficient and the rapid and extensive development of resistance to the existing drugs has raised 
great public health concern. There is therefore an urgent need to develop new antiviral strategies 
targeting other processes in the IV life cycle. Current research efforts include (i) the improvement 
of existing drugs; (ii) the development of inhibitors against other antiviral targets, in particular 
RdRP, NP, and NS1; (iii) strategies to block virus-cell interactions occurring at different stages of 
IV replication, such as attachment, entry, viral genome transcription and replication, nuclear export 
of viral products, and viral particles release; and (iv) modulation of cell metabolism and host 
antiviral response. In addition, like for other fast mutating viruses such as HIV and HCV, the 
application of antiviral drugs in combination, with different mechanisms of action, is being actively 
pursued, as it could be more effective in treating virulent and pandemic IV strains. Given the broad 
array of different anti-IV strategies under development, it is our hope that the discovery of new 
drugs will very soon provide wider options for improved prophylactic and therapeutic approaches 
against influenza infection. 
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Figure legends  
 
Fig. 1.  Antiviral strategies targeting viral functions essential for IV replication. 
The first step of IV infection is the interaction between viral HA and cellular SA-containing 
receptors, resulting in the attachment of the virion to the target cell. Attachment inhibitors, such as 
mAb directed against the globular head of HA, natural and synthetic compounds containing SA, 
HA-binding peptides, and compounds that recognize glycosylation sites of HA, interfere with this 
process and block IV infection. After the internalization of the virion, HA mediates the fusion of the 
viral envelope with the endosomal membrane, a pH-dependent process that can be inhibited by 
fusion inhibitors such as small molecules that inhibit the low pH-induced conformational change of 
HA (e.g., ARB), neutralizing mAbs directed against the stem region of HA, and high-molecular-
weight molecules that prevent the fusion by steric hindrance. The activity of the viral protonic pump 
M2 leads to the acidification of the endosome and to the viral uncoating, followed by the release of 
the vRNP into the cytoplasm. M2 inhibitors such as adamantanes block IAV (but not IBV) 
replication at this step. After nuclear translocation of the vRNP, the viral genomic segments are 
transcribed by the viral RdRP into mRNAs that are then transported into the cytoplasm and 
translated into viral proteins necessary for viral genome replication, also catalyzed by viral RdRP. 
Small molecules able to interfere with RdRP complex activities can inhibit both transcription and 
replication steps. Transcription, replication, correct assembly of vRNPs, and their nuclear export 
require the activity of viral NP. Also small molecules targeting NP functions have demonstrated 
effective anti-influenza activity. After the assembly of new virions, they are transported at the cell 
membrane and then released by budding process. The activity of NA present on the virion surface is 
essential for the cleavage of SA molecules from HA and to allow the release of viral particles. NA 
inhibitors such as zanamivir and oseltamivir block IAV and IBV replication by interfering with this 
step.  
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Fig. 2.  Antiviral strategies involving host factors engaged in IV replication. 
IV infection can be inhibited by inhibitors of extracellular proteases responsible of HA activation. 
Fludase interfers with the interaction of viral HA to cellular SA-containing receptors, while 
tyrosine-kinase receptors and EGFR inhibitors, as well as chemical inhibitors of endocytosis and 
macropinocytosis processes block the endosomal internalization of the virus particle. vATPase 
inhibitors have shown activity against the pH-dependent fusion step that allows viral uncoating and 
also proteasome inhibitors might have an inhibitory effect on the latter process. After the nuclear 
import of vRNPs, the first step is the transcription of the viral genome into viral mRNA and this 
process is catalyzed by RdRP with the involvement of the cellular RNA polymerase II and 
transcription elongation factor pTEF1b. Inhibitors of both RNA polymerase II and pTEF1b 
complex are able to interfere with this process and to block viral mRNA synthesis. Viral mRNAs 
are then exported into the cytoplasm and translated into viral proteins required for the viral genome 
replication, which takes place into the nucleus. At this stage, Hsp90 inhibitors can be effective in 
blocking the nuclear import of viral proteins. The newly synthesized vRNPs have then to be 
exported into the cytoplasm to be assembled into the new virions. Small molecule inhibitors of 
cellular Crm1 and SGK1 proteins involved in the vRNPs export can inhibit this step. Antioxidants 
able to restore the cellular redox potential and intracellular protease inhibitors interfere with the 
correct processing and maturation of HA; in addition, inhibitors of mitochondrial DHODH, an 
enzyme of the pyrimidine biosynthetic pathway, have demonstrated anti-influenza activity. Also the 
soluble lipid mediator PD1 is able to inhibit IV replication by interfering with the nuclear export of 
viral transcripts mediated by the cellular protein NFX1. Finally, compounds that interfere with 
proper lipid raft formation at the plasma membrane have also shown the ability to block IV 
budding. 
 
Fig. 3.  Antiviral strategies involving host signaling pathways, metabolism, and antiviral 
defense. 
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IV infection triggers the activation of a series of cellular signaling pathways as well as the IFN-
dependent antiviral response. PKC and COX-2 pathways are activated directly upon infection, 
while the oxidative stress that follows viral infection activates several redox-sensitive cellular 
pathways, such as NF-κB, PI3K, and MAPKs. COX-2 inhibitors have demonstrated to inhibit both 
IV replication and viral-induced inflammation and cytokine production. PKC inhibitors are able to 
interfere with post-fusion events and endocytosis after virion internalization. Antioxidants that 
interfere with redox-sensitive cellular processes also interfere with viral functions such as vRNPs 
trafficking and nuclear export, as well as HA maturation, thus blocking viral replication. 
Furthermore, IV replication in the host cell activates the UPR in the ER, which can be counteracted 
by chemical chaperones that alleviate ER stress and have shown anti-influenza activity. The 
antiviral response activated by IV is dependent on IFN cascade activation and initiates with the 
recognition of viral patterns by the TLR-3, -7, and -9 on the cell membrane and by cytoplasmic 
RLRs, which act as sensors of viral invasion. TLRs and RLRs agonists as well as CpG ODNs have 
shown anti-influenza activity by stimulating the IFN response. The viral NS1 protein antagonizes 
this antiviral response, thus antiviral strategies either targeted against this protein or involving the 
activation of IFN pathway have inhibitory effects on IV replication. 
 
